NasdaqGS:CGONBiotechs
Assessing CG Oncology (CGON) Valuation After Positive CORE-008 Phase 2 Bladder Cancer Data
CG Oncology (CGON) shares have been reacting to fresh clinical data, after the company reported early CORE-008 Phase 2 results for cretostimogene grenadenorepvec plus gemcitabine in high-risk non muscle invasive bladder cancer.
See our latest analysis for CG Oncology.
The recent CORE-008 data release has arrived after a strong run, with CG Oncology’s year to date share price return of 53.74% and a very large 1 year total shareholder return of 151.76%. This suggests that optimism around...